Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Kristina Graudenz"'
Autor:
Gary Wilkinson, Robert Fricke, Timo Korjamo, Mikko Koskinen, Olaf Prien, Hille Gieschen, Kristina Graudenz, Karsten Denner, Michaela Bairlein, Clemens-Jeremias Von Bühler, Christian Zurth
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics
Background and Objectives Darolutamide is a novel androgen receptor (AR) antagonist approved for the treatment of nonmetastatic castration-resistant prostate cancer (nmCRPC). Accordingly, the drug–drug interaction (DDI) potential of darolutamide wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1958f97ab799d34b65b089ca72f88b2
https://doi.org/10.1007/s13318-019-00577-5
https://doi.org/10.1007/s13318-019-00577-5
Autor:
Olaf Prien, Iris Kuss, Kristina Graudenz, Karim Fizazi, Bart Ploeger, Gustavo Borghesi, Teuvo L.J. Tammela, Neal D. Shore, Robert Fricke, Jonathan Moss, Hille Gieschen, Oana Petrenciuc, Frank Verholen, Christian Zurth, Mikko Koskinen, Matthew R. Smith
Publikováno v:
Targeted Oncology
Background Darolutamide, an androgen receptor antagonist with a distinct molecular structure, significantly prolonged metastasis-free survival versus placebo in the phase III ARAMIS study in men with nonmetastatic castration-resistant prostate cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ac2f03eb3e89dd93f921111daaa43d3
https://pubmed.ncbi.nlm.nih.gov/31571095
https://pubmed.ncbi.nlm.nih.gov/31571095
Autor:
Steven Williams, Owen O'Daly, Christian Zurth, Kristina Graudenz, Fiona Patrick, Patricia Cole, Ndaba Mazibuko, Iris Kuss, Caroline Wooldridge
Publikováno v:
Journal of Clinical Oncology. 38:326-326
326 Background: DARO is an oral androgen receptor antagonist with a unique structure and a low blood–brain barrier penetrance noted in rodents. Here we compare CBF following administration of DARO, ENZA, and PBO using arterial spin labelled magneti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::373fa621d6678a557dc4be3bdcef025b
https://doi.org/10.1200/jco.2020.38.6_suppl.326
https://doi.org/10.1200/jco.2020.38.6_suppl.326
Autor:
Funan Huang, Carol Peña, Jan Eucker, Carlos Gomez-Roca, Frederik Marmé, Kristina Graudenz, Zuzana Jirakova Trnkova, John Lettieri
Publikováno v:
Cancer chemotherapy and pharmacology. 81(4)
Combining sorafenib and eribulin mesylate may provide synergistic antitumor activities with limited overlapping toxicities. This phase 1b, open-label, dose-escalation study evaluated safety, pharmacokinetics, maximum tolerated dose/recommended phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ce36b13d586ec1c1fac697a4c3c4a98
https://pubmed.ncbi.nlm.nih.gov/29468456
https://pubmed.ncbi.nlm.nih.gov/29468456
Autor:
Robert Fricke, Matthew R. Smith, Kristina Graudenz, Bart Ploeger, Teuvo L.J. Tammela, Mikko Koskinen, Christian Zurth, Olaf Prien, Karim Fizazi, N.D. Shore, Hille Gieschen
Publikováno v:
Annals of Oncology. 30:v350
Background DARO is an androgen receptor antagonist with a distinct molecular structure, which has demonstrated prolonged metastasis-free survival vs placebo (PBO) in the phase 3 ARAMIS study in non-metastatic castration-resistant prostate cancer pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::919408217af5f27f88dd626ebb3e5f78
https://doi.org/10.1093/annonc/mdz248.047
https://doi.org/10.1093/annonc/mdz248.047
Autor:
Gary Wilkinson, Timo Korjamo, Karsten Denner, Christian Zurth, Robert Fricke, Friedeborg Seitz, Olaf Prien, Kristina Graudenz
Publikováno v:
Journal of Clinical Oncology. 37:297-297
297 Background: Maintaining quality of survival, by delaying disease progression and minimizing therapy burden, is critical for patients and has been evaluated in the pivotal phase III ARAMIS study in patients with non-metastatic castration-resistant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f5808b39ec3b4e309f1c8a044a10a1cd
https://doi.org/10.1200/jco.2019.37.7_suppl.297
https://doi.org/10.1200/jco.2019.37.7_suppl.297
Publikováno v:
Proceedings for Annual Meeting of The Japanese Pharmacological Society. :OR22-2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9c1244ea61df1b7d1f7dc01f464a8b50
https://doi.org/10.1254/jpssuppl.wcp2018.0_or22-2
https://doi.org/10.1254/jpssuppl.wcp2018.0_or22-2